FILE:LH/LH-8K-20090423090908.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
This Form 8-K/A is being filed to to amend and restate in its entirety the registrant's Form 8-K filed April 23, 2009 in order to correct certain errors in the prior filing.
ITEM 7.01. Regulation FD Disclosure
Amended summary information of the Company dated April 23, 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
1
8-K/A Filed April 23, 2009
2
Introduction
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.  
Actual results could differ materially from those suggested by these forward-looking statements.  Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2008, and subsequent SEC filings. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.
3
First Quarter Results
(In millions, except per share data)
4
Cash Flow Trend
10% OCF CAGR
2004-2008
5
Revenue by Payer- US 2009 Q1
(In millions)
6
Revenue by Business Area - US 2009 Q1
(In millions)
7
Revenue by Payer
(in millions, except PPA)
8
Revenue by Business Area  
(in millions, except PPA)
9
Financial Guidance - 2009
          
Excluding the impact of restructuring and other special charges and share repurchase activity after December 31, 2008, guidance for 2009 is:
  Revenue growth:
2-4%
  Diluted earnings per share:
$4.75 to $4.95
  Operating cash flow of approximately
(1)
:
$800 million
  Capital expenditures of approximately:
$130 million
          
(1) Operating cash flow guidance excludes any transition payments to UnitedHealthcare and includes a $54.8 million reduction due to required contributions to the Company's defined benefit retirement plan.
10
Supplemental Financial Information
11


